{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:57Z","timestamp":1786986957465,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1R01DK117881-01"],"award-info":[{"award-number":["1R01DK117881-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008318","name":"Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["1U01AA026972-02"],"award-info":[{"award-number":["1U01AA026972-02"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["5U01AA026264-02"],"award-info":[{"award-number":["5U01AA026264-02"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["1U01AA026978-01"],"award-info":[{"award-number":["1U01AA026978-01"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cld.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T11:19:16Z","timestamp":1622114356000},"page":"537-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Moderate Alcoholic Hepatitis"],"prefix":"10.1016","volume":"25","author":[{"given":"Ana","family":"Clemente-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Oliveira-Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.03.001_bib2","series-title":"Global status report on alcohol and health","first-page":"2018","volume":"65","author":"Hammer","year":"2018"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","article-title":"Global burden of alcoholic liver diseases","volume":"59","author":"Rehm","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2021.03.001_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2011.134","article-title":"Alcoholic liver disease: pathogenesis and new targets for therapy","volume":"8","author":"Altamirano","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.03.001_bib7","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis","volume":"41","author":"Dunn","year":"2005","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2021.03.001_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gut.2004.050781","article-title":"Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow Alcoholic Hepatitis Score","volume":"54","author":"Forrest","year":"2005","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.cld.2021.03.001_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2007.03258.x","article-title":"Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis","volume":"25","author":"Rincon","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.cld.2021.03.001_bib11","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2008.02104.x","article-title":"A\u00a0new scoring system for prognostic stratification of patients with alcoholic hepatitis","volume":"103","author":"Dominguez","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2021.03.001_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A\u00a0histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib13","first-page":"161","article-title":"Clinical characteristics and outcomes of mild to moderate alcoholic hepatitis","volume":"1","author":"Samala","year":"2019","journal-title":"GastroHep"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/apt.15376","article-title":"Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis","volume":"50","author":"Bennett","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2019.12.023","article-title":"Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey\u2019s discriminant function <32","volume":"72","author":"Degre","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2021.03.001_bib16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2021.03.001_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ebiom.2019.03.046","article-title":"Obesity in acute alcoholic hepatitis increases morbidity and mortality","volume":"45","author":"Parker","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.cld.2021.03.001_bib18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A\u00a0model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2021.03.001_bib21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3109\/00365521.2011.587200","article-title":"Validation of prognostic scores for clinical use in patients with alcoholic hepatitis","volume":"46","author":"Sandahl","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2021.03.001_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/apt.12654","article-title":"Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort","volume":"39","author":"Papastergiou","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2021.03.001_bib23","doi-asserted-by":"crossref","first-page":"624675","DOI":"10.1155\/2012\/624675","article-title":"The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway?","volume":"2012","author":"Palaniyappan","year":"2012","journal-title":"Int J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2017.11.017","article-title":"Application of prognostic scores in the STOPAH trial: discriminant function is no longer the optimal scoring system in alcoholic hepatitis","volume":"68","author":"Forrest","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.03.001_bib25","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.29338","article-title":"Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival","volume":"66","author":"Altamirano","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.1840070408","article-title":"Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics","volume":"7","author":"Infante-Rivard","year":"1987","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib27","doi-asserted-by":"crossref","first-page":"e0192393","DOI":"10.1371\/journal.pone.0192393","article-title":"Survival from alcoholic hepatitis has not improved over time","volume":"13","author":"Hughes","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/cld.172","article-title":"Histopathology of alcoholic liver disease","volume":"2","author":"Theise","year":"2013","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28\u00a0days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2021.03.001_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S2468-1253(19)30326-7","article-title":"The knowns and unknowns of treatment for alcoholic hepatitis","volume":"5","author":"Sehrawat","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.03.001_bib31","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14309\/ajg.0000000000000492","article-title":"Serum transferrin is an independent predictor of mortality in severe alcoholic hepatitis","volume":"115","author":"Atkinson","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0676.2003.01804.x","article-title":"Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence","volume":"23","author":"Pessione","year":"2003","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib34","first-page":"210","article-title":"Prognostic factors in alcoholic liver disease. VA Cooperative Study Group","volume":"86","author":"Chedid","year":"1991","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.03.001_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/MEG.0b013e32835d83d9","article-title":"Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes","volume":"25","author":"Potts","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.03.001_bib37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/apt.12427","article-title":"Determinants of long-term outcome in severe alcoholic hepatitis","volume":"38","author":"Potts","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/liv.14265","article-title":"Gene signature-MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis","volume":"40","author":"Deltenre","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cgh.2015.07.047","article-title":"Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review","volume":"14","author":"Khan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.03.001_bib40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S2468-1253(19)30415-7","article-title":"Outpatient management of alcohol-related liver disease","volume":"5","author":"Simonetto","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cgh.2019.04.048","article-title":"Alcohol rehabilitation within 30\u00a0days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis","volume":"18","author":"Peeraphatdit","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cld.2018.09.004","article-title":"Alcohol use disorders in alcoholic liver disease","volume":"23","author":"Mellinger","year":"2019","journal-title":"Clin Liver Dis"},{"issue":"9603","key":"10.1016\/j.cld.2021.03.001_bib43","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/alcalc\/agu028","article-title":"Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis","volume":"49","author":"Yamini","year":"2014","journal-title":"Alcohol Alcohol"},{"issue":"11","key":"10.1016\/j.cld.2021.03.001_bib45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pds.4635","article-title":"Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France","volume":"27","author":"Chaignot","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cld.571","article-title":"Biomarkers for monitoring alcohol use","volume":"8","author":"Cabezas","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2021.03.001_bib47","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019;70(1):172-93.","DOI":"10.1016\/j.jhep.2018.06.024"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jhep.2013.03.024","article-title":"Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease","volume":"59","author":"Tr\u00e9po","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12937-019-0461-3","article-title":"Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis","volume":"18","author":"Shen","year":"2019","journal-title":"Nutr J"},{"issue":"4","key":"10.1016\/j.cld.2021.03.001_bib50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2015.12.038","article-title":"Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids","volume":"150","author":"Moreno","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG clinical guideline: alcoholic liver disease","volume":"113","author":"Singal","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib52","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.03.001_bib53","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018;69(1):154-81.","DOI":"10.1016\/j.jhep.2018.03.018"},{"key":"10.1016\/j.cld.2021.03.001_bib54","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J\u00a0Hepatol 2018;69(2):406-60.","DOI":"10.1016\/j.jhep.2018.08.009"},{"issue":"3","key":"10.1016\/j.cld.2021.03.001_bib55","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.27779","article-title":"Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis","volume":"62","author":"Michelena","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.03.001_bib56","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","article-title":"In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA","volume":"152","author":"Vergis","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2021.03.001_bib57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.03.001_bib59","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatocellular carcinoma. J\u00a0Hepatol 2018;69(1):182-236.","DOI":"10.1016\/j.jhep.2018.03.019"},{"issue":"5","key":"10.1016\/j.cld.2021.03.001_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(19)30451-0","article-title":"Liver transplantation in patients with alcohol-related liver disease: current status and future directions","volume":"5","author":"Mathurin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.001_bib61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.03.001_bib62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handbook of experimental pharmacology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:35:16Z","timestamp":1778798116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1089326121000155"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.03.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderate Alcoholic Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}